NEDA-3 and treatment goals

No Evidence Of Disease Activity (NEDA): the goal of Multiple Sclerosis (MS) treatmentПодробнее

The predictive value of NEDA-3 for long-term disability in MSПодробнее

What is NEDA and How Does it Help Patient CareПодробнее

sNfL identifies patients at higher risk of future disease activity beyond NEDA-3 statusПодробнее

MS Research: Does Treating MS Actually Make a Difference??Подробнее

Evaluation of sNfL in MS patients with NEDA-3Подробнее

Stornoway healthcare professionals day: Treating to a target of NEDA by Klaus SchmiererПодробнее

Treatment of Multiple SclerosisПодробнее

Understanding Treatment GoalsПодробнее

BBB permeability changes predict treatment response to alemtuzumab in RRMSПодробнее

Harnessing the Full Potential of DMT Mechanisms of Action to Improve MS OutcomesПодробнее

NEDA-No Evidence of Disease ActivityПодробнее

sNfL predicts NEDA-status in a 6-year longitudinal cohort of MS patientsПодробнее

Treating beyond NEDA to tackle the unmet need of smouldering MSПодробнее

The Progression of Multiple Sclerosis in Young Women and NEDAПодробнее

NEDA tweaks goals under PH dev't plan amid pandemicПодробнее

Multiple Sclerosis Vlog: Goal-Setting Strategies in MSПодробнее

Goals of Therapy in Multiple SclerosisПодробнее

Best MS Medication?Подробнее